Connect Biopharma Holdings Limited (NasdaqGM: CNTB)
Health Care · Biotechnology · US
$0.76
-4.51% today · -51.0% 1Y
Connect Biopharma Holdings Limited (NasdaqGM: CNTB) operates in the Biotechnology industry within the Health Care sector. The company is valued at $47.99M and employs 64 people.
Over the last twelve months the share price has lost 51.0%, trading between 0.73 and 3.82.
Tweenvest scores Connect Biopharma Holdings Limited across four factors: quality 37/100, value 59/100. Its strongest factor is value.
CNTB price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $47.99M
- Revenue (TTM)
- $2.95M
- P/E
- —
- EPS
- -1.19
- Dividend yield
- —
- Beta (5Y)
- —
- 52-week high
- $3.82
- 52-week low
- $0.73
- Avg volume (3M)
- —
- Shares outstanding
- 62.97M
- Employees
- 64
- Next earnings
- —
About Connect Biopharma Holdings Limited
Connect Biopharma Holdings Limited is a clinical-stage biopharmaceutical company dedicated to discovering and advancing immune modulators. Its primary objective is to develop treatments for serious autoimmune diseases and various inflammatory conditions. The company's lead investigational therapy is CBP-201, an anti-interleukin-4 receptor alpha antibody. This candidate is currently in Phase IIb clinical trials, targeting inflammatory allergic diseases such as atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps. Additionally, Connect Biopharma's pipeline includes CBP-307, a small molecule designed to modulate sphingosine 1-phosphate receptor 1. This receptor plays a crucial role in regulating T cell movement from lymph nodes into the bloodstream. CBP-307 is in Phase II development for treating autoimmune-related inflammatory disorders. Another preclinical-stage asset, CBP-174, is an orally administered small molecule histamine receptor 3 antagonist, being investigated for chronic pruritus (itch) associated with skin inflammation. The portfolio also features CBP-233, a humanized antibody in preclinical development that targets interleukin-33, a cytokine recognized for its involvement in T helper 2 inflammation. Established in 2012, the company maintains its headquarters in Taicang, China.
- ISIN
- KYG235491019
- Founded
- 2012
- Listed since
- Mar 19, 2021
- Exchange
- Nasdaq Global Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Amicogen, Inc.KOSDAQ: A092040 | $48.83M | ₩924.00 | -6.29% |
| Optipharm.CO.,LTDKOSDAQ: A153710 | $48.80M | ₩4,435.00 | -1.22% |
| GENINUS Inc.KOSDAQ: A389030 | $48.75M | ₩1,650.00 | -15.38% |
| MiNK Therapeutics, Inc.NasdaqCM: INKT | $48.02M | $9.41 | -12.22% |
| HLB Panagene Co., Ltd.KOSDAQ: A046210 | $47.81M | ₩1,400.00 | -21.08% |
| Sangamo Therapeutics, Inc.OTCPK: SGMO.Q | $47.64M | $0.12 | +9.52% |
| Werewolf Therapeutics, Inc.NasdaqCM: HOWL | $47.63M | $0.98 | +0.04% |
| Kalaris Therapeutics, Inc.NasdaqGM: KLRS | $47.61M | $2.00 | -15.25% |
Figures last refreshed Oct 18, 2026.